Tori N. Yamamoto

Gladstone Institutes — United States

Medicine · Health Sciences

23h-index5.2kcitations46works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(26), Immune Cell Function and Interaction(22), Immunotherapy and Immune Responses(14), Cancer Immunotherapy and Biomarkers(11), Virus-based gene therapy research(7)

Publications45 total

Modular pooled discovery of synthetic knockin sequences to program durable cell therapies
Cell·2023· 61 citedOpen Access
Supplementary Figure Legend from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
CCR Translation for This Article from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
CCR Translation for This Article from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
Supplementary Table from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
Supplementary Figure Legend from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
Supplementary Figs 1, 2 from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
Supplementary Figs 1, 2 from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
2023Open Access
Cancer genes disfavoring T cell immunity identified via integrated systems approach
Cell Reports·2022· 14 citedOpen Access
An engineered IL-2 partial agonist promotes CD8+ T cell stemness
Nature·2021· 171 citedOpen Access
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Nature Biotechnology·2020· 297 citedOpen Access
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies
Cancer Cell·2020· 150 citedOpen Access
An engineered IL-2 partial agonist promotes CD8+ T cell stemness and anti-tumor efficacy
The Journal of Immunology·2020
Test performance evaluation of SARS-CoV-2 serological assays
2020· 253 citedOpen Access
Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy
2019
Developing neoantigen-targeted T cell–based treatments for solid tumors
Nature Medicine·2019· 235 cited
Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells
The Journal of Experimental Medicine·2019· 76 citedOpen Access
Mg2+ regulation of kinase signaling and immune function
The Journal of Experimental Medicine·2019· 81 cited
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Science·2019· 511 citedOpen Access
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Journal of Clinical Investigation·2019· 153 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Nicholas P. Restifo(21), Zhiya Yu(12), Suman K. Vodnala(11), Christopher A. Klebanoff(11), Robert Eil(10), Madhusudhanan Sukumar(10), Qunrui Ye(10), Shashank J. Patel(8), Rigel J. Kishton(8), De-Gang Song(8), Mathilde Poussin(8), George Coukos(8), Stanley R. Riddell(7), Andrew Best(7), Douglas C. Palmer(6), Anthony Cruz(6), Luca Gattinoni(6), Richard M. Siegel(6), Devikala Gurusamy(6), David Clever(5)